Is TB-500 Legal in Washington State? Federal Rules, Prescription Paths, and What Patients Need to Know

HealthRX.com

No Washington permission confirmed; the federal draft is not binding

Print or save as PDF

See the public record for TB-500

  • FDA approval / No FDA-approved TB-500 product, and no approved product in Canada, Australia, the UK or the European countries FDA reviewed; the European Medicines Agency has not authorized one [1]
  • What it is / A synthetic 7-amino-acid fragment of thymosin beta-4 [1]
  • FDA bulks lists / Not listed for state-licensed pharmacies or outsourcing facilities [2][3][6]
  • Safety-risk page / 'Nominated but withdrawn' table, not an active listing [7]
  • Advisory committee / Voted in favor July 23, 2026; advice only [4][8]
  • HHS draft policy / Names TB-500 acetate injection; non-binding draft [4][5]
  • Anti-doping / WADA prohibits it at all times [9]

Where TB-500 stands federally

FDA's July 2026 review found no USP or National Formulary monograph for TB-500, no FDA-approved drug containing it, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy or authorized by the European Medicines Agency [1]. TB-500 is a synthetic 7-amino-acid fragment (residues 17 to 23) of the 43-amino-acid protein thymosin beta-4, not the full-length protein [1].

It appears in none of the three categories of FDA's interim policy for state-licensed pharmacies and physicians (updated May 14, 2026) and is absent from FDA's list for outsourcing facilities (updated March 21, 2025), so that policy of generally not acting against compounders does not cover it [2][3][6]. FDA's safety-risk page lists 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' in its 'nominated but withdrawn' table; removal was not a finding that it is safe, and FDA said it 'has not identified any human exposure data' on it [7].

The 2026 developments, and what they are not

FDA staff proposed in July 2026 that neither TB-500 free base nor TB-500 acetate be added to the pharmacy bulks list, citing unclear characterization, no evidence of effectiveness for wound healing, and no human data [1]. The Pharmacy Compounding Advisory Committee voted in favor of adding it on July 23, 2026, against staff's recommendation; the vote is advice only and not binding [4][8].

In its non-binding draft policy, HHS proposes not to take enforcement action against certain prescribers and pharmacies compounding TB-500 acetate injections if all stated conditions are met, including a patient-specific prescription [4][5]. The notice states it 'does not establish any rights for any person and is not binding on HHS or the public' [4].

What people on Reddit report

Reddit users discussing the federal enforcement discretion policy for six compounded peptides. Accounts range from people who see it as a legal route to people who expect prices to rise or access to narrow.

RUOrescue · TeleMedicine

This is a pathway for more LEGIT access. Im sorry but this RUO business is saturated with "Gym Bro Joe" slinging god knows what

Supports the policy as a way for doctors to prescribe compounded peptides and for patients to get tested product.

Read the source discussion

bangwhosnext · TeleMedicine

If they wipe out the "RUO's" people will be left with no choice but to pay extravagant prices that they can't afford. Many won't even get a prescription or approved for these peptides.

Worries that the prescription route will be costly and that many people will not qualify for it.

Read the source discussion

livlyla · TeleMedicine

The RUO side is not going anywhere. The pharmacies and med spas will charge way more than an RUO site.

Expects research-use sellers to remain because compounded versions cost more.

Read the source discussion

dispenseflow · TeleMedicine

It's 503A only. 503B outsourcing facilities aren't covered, so no office-use stock or big batch production. Every fill is patient-specific off a script.

Describes the compounding category the policy covers and that each fill needs an individual prescription.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

Safety: what is known

There is no approved dose and no human dosing study; the nomination FDA reviewed proposed a 3 mg/mL lyophilized powder for injection [1]. FDA found no published article in which TB-500 was given to a person, and its adverse-event database search through March 26, 2025 retrieved no TB-500 reports [1]. Safety in humans is unknown; FDA's stated concern for injectable TB-500 is immunogenicity, possibly amplified by aggregation and impurities [1].

Athletes

WADA names 'Thymosin-beta4 and its derivatives e.g. TB-500' in section S2.3 and prohibits it at all times, in and out of competition; it is on the 2026 List and stays on the 2027 List [9][10]. Compounded drugs, even when made under an enforcement-discretion policy, are not FDA-approved [4].

Is TB-500 legal in Washington State?
Washington-specific permission cannot be confirmed. TB-500 is not FDA-approved, and an HHS draft proposing limited, conditional enforcement discretion for compounded TB-500 acetate injections is not an approval or a binding ruling on state law [1][4][5].
Does TB-500 require a prescription?
The HHS draft policy for TB-500 acetate injection lists a patient-specific prescription among its conditions [5]. No FDA-approved TB-500 product exists, and compounded drugs are not FDA-approved [1][4].
Did FDA approve TB-500 for compounding in 2026?
No. FDA staff recommended against adding it to the bulks list, and the advisory committee voted in favor on July 23, 2026; that vote is advice only [1][8]. Adding a substance takes formal rulemaking, and TB-500 is not on the list [8][4].
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a synthetic 7-amino-acid fragment, residues 17 to 23, of the 43-amino-acid protein [1]. Human studies of full-length thymosin beta-4, such as eye-drop and intravenous recombinant products, do not show that TB-500 works or is safe [1].
Can athletes use TB-500?
WADA names thymosin-beta4 and its derivatives, for example TB-500, in section S2.3 and prohibits it at all times, in and out of competition [9]. It is on the 2026 List and stays on the 2027 List [9][10].
Show all 11 referencesHide references
Evidence overview for Is TB-500 Legal in Washington State? Federal Rules, Prescription Paths, and What Patients Need to Know